Companies / EVGN
Evogene Ltd. (EVGN)
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Ticker EVGN Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $9.20M 52-week range $0.25 - $1.26
Valuation Share price $0.35 (close of Nov 18, 2026) P/E (TTM) -0.75x Price to book 1.60x Price to free cash flow -0.84x Enterprise value $1.99M Book value per share $0.21
Price performance Period Change 1 day +2.94% 5 days -12.50% 1 month -10.26% 3 months -39.66% 6 months -50.00% Year to date -68.18% 1 year -70.09% 3 years -94.70% 5 years -98.33% 10 years -99.40% All time -99.64%
Short interest As of Oct 30, 2026 Short % of float 0.39% Shares short 70.32K Days to cover 2.33 Change since prior report +10.08% Source FINRA consolidated short interest
Profitability and growth Return on equity -70.86% Return on invested capital -99.02% Return on assets -42.33% Return on capital employed -84.53% Gross margin -6.25% Net margin -220.22% EBITDA margin -350.69% Revenue growth -30.91%
Cash flow and balance sheet Free cash flow yield (TTM) -119.18% Current ratio 3.57x Net debt to EBITDA 0.64x
Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $3.85M Cost of revenue $4.09M Gross profit -$241.00K EBITDA -$13.51M Net income -$8.48M Research and development $7.99M Interest expense $1.93M
Income statement by year Period end Revenue Gross profit Net income 2025-12-31 $3.85M -$241.00K -$8.48M 2024-12-31 $5.58M - -$16.48M 2023-12-31 $2.98M - -$23.88M 2022-12-31 $1.68M - -$26.64M 2021-12-31 $930.00K - -$27.79M 2020-12-31 $1.04M - -$23.37M 2019-12-31 $753.00K - -$18.11M 2018-12-31 $1.75M - -$20.76M 2017-12-31 $3.38M - -$20.84M 2016-12-31 $6.54M - -$19.59M
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 -6.25% -220.22% -70.86% -99.02% 2024-12-31 - -295.59% -111.10% -67.86% 2023-12-31 - -800.77% -83.25% -55.31% 2022-12-31 - -1,590.33% -76.57% -57.66% 2021-12-31 - -2,988.49% -43.82% -46.84% 2020-12-31 - -2,247.50% -41.09% -41.83% 2019-12-31 - -2,405.31% -30.08% -33.50% 2018-12-31 - -1,188.21% -41.26% -39.73% 2017-12-31 - -616.33% -30.04% -31.63% 2016-12-31 - -299.57% -22.44% -24.16%
Cash and debt by year Period end Cash 2025-12-31 $12.96M 2024-12-31 $15.30M 2023-12-31 $20.77M 2022-12-31 $28.98M 2021-12-31 $32.33M 2020-12-31 $46.23M 2019-12-31 $34.75M 2018-12-31 $5.81M 2017-12-31 $3.44M 2016-12-31 $3.24M
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$13.64M $654.00K 2024-12-31 -$20.33M $1.24M 2023-12-31 -$22.15M $1.11M 2022-12-31 -$24.85M $1.19M 2021-12-31 -$25.56M $2.61M 2020-12-31 -$20.20M $4.10M 2019-12-31 -$18.57M $1.58M 2018-12-31 -$15.54M $1.73M 2017-12-31 -$16.52M $2.24M 2016-12-31 -$12.50M $2.94M
Investor relations Next earnings report Next confirmed report Nov 19, 2026 Consensus EPS estimate $-0.19 Past earnings dates Reported Fiscal period EPS estimate 2026-08-18 Jun 2026 - 2026-05-20 Mar 2026 - 2026-03-05 Dec 2025 - 2025-11-20 Sep 2025 - 2025-08-19 Jun 2025 - 2025-05-21 Mar 2025 - 2025-03-06 Dec 2024 - 2024-11-21 Sep 2024 -
Filings and sources Company website evogene.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports
Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades